• Signed cohort-specific Informed Consent Form

• Age \>= 18 years at time of signing Informed Consent Form

• Biomarker eligibility as determined by:

‣ A validated test approved by local health authorities for detection of the specified biomarkers/mutations.

⁃ A validated test performed at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA) -certified or equivalently accredited diagnostic laboratory using a validated test for detection of the specified biomarkers.

⁃ Prior test results completed before signing cohort-specific Informed Consent Form or local test results generated prior to or during screening, and availability of a full report of the testing results OR

⁃ Blood-based FoundationOne Liquid CDx biomarker eligibility test result generated prior to or during screening or, in case of re-enrollment after treatment discontinuation, prior to starting a new anti-cancer therapy.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of \<= 1

• Life expectancy \>= 3 months, as determined by the investigator

• Histologically confirmed adenocarcinoma originating from the colon or rectum

• Metastatic disease

• Prior therapies for metastatic disease

• Ability to comply with the study protocol, in the investigators judgment

• Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

• Baseline tumor tissue samples will be collected from all participants for exploratory biomarker research

• Adequate hematologic and organ function within 14 days prior to initiation of study treatment

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures

• For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm